AbbVie's Phase 2 PICCOLO trial of mirvetuximab soravtansine for platinum-sensitive ovarian cancer patients demonstrated a 51.9% objective response rate and 8.
AbbVie's Phase 2 PICCOLO trial of mirvetuximab soravtansine (Elahere) for platinum-sensitive ovarian cancer patients showed positive results, with a 51.9% objective response rate and a median duration of response of 8.25 months. The trial's safety profile was consistent with previous studies, and no new safety concerns were identified. AbbVie plans to present full data at a future medical meeting.
June 06, 2024
6 Articles